Burn, John, Sheth, Harsh, Gerdes, Anne-Marie, Ho, Judy W. C., Lindblom, Annika, Morrison, Patrick J., Rashbass, Jem, Ramesar, Raj, Seppälä, Toni, Thomas, Huw J. W., Pylvänäinen, Kirsi, Borthwick, Gillian M., Elliott, Faye, Mathers, John C., Bishop, DT, Boussioutas, A, Brewer, C, Cook, J, Eccles, D, Ellis, A, Hodgson, SV, Lubinski, J, Maher, ER, Reed, Lynn, Porteous, ME, Sampson, J, Scott, RJ, Side, L, Macrae, Finlay, Mecklin, Jukka-Pekka, Möslein, Gabriela, McRonald, Fiona E., Bertario, Lucio, Evans, D. Gareth. Lancet; 2020. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial.

Burn, John, Bishop, Timothy, Bertario, Lucio, Jarvinen, Heikki J., Lindblom, Annika, Evans, D. Gareth, Lubinski, Jan, Morrison, Patrick J., Ho, Judy W. C., Vasen, Hans F. A., Side, Lucy, Thomas, Huw J. W., Mecklin, Jukka-Pekka, Scott, Rodney J., Dunlop, Malcolm, Barker, Gail, Elliott, Faye, Jass, Jeremy R., Fodde, Ricardo, Lynch, Henry T., Mathers, John C., Macrae, Finlay, Moslein, Gabriela, Olschwang, Sylviane, Bisgaard, Marie-Luise, Ramesar, Raj, Eccles, Diana, Maher, Eamonn R.. Massachusetts Medical Society; 2008. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.

Burn, John, Gerdes, Anne-Marie, Bisgaard, Marie Louise, Dunlop, Malcolm G., Ho, Judy W. C., Hodgson, Shirley V., Lindblom, Annika, Lubinski, Jan, Morrison, Patrick J., Murday, Victoria, Ramesar, Raj, Side, Lucy, Macrae, Finlay, Scott, Rodney J., Thomas, Huw J. W., Vasen, Hans F., Barker, Gail, Crawford, Gillian, Elliott, Faye, Movahedi, Mohammad, Pylvanainen, Kirsi, Wijnen, Juul T., Fodde, Riccardo, Mecklin, Jukka-Pekka, Lynch, Henry T., Mathers, John C., Bishop, D. Timothy, Moeslein, Gabriela, Olschwang, Sylviane, Eccles, Diane, Evans, D. Gareth, Maher, Eamonn R., Bertario, Lucio. Lancet Publishing Group; 2011. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.